KNOW Bio announces breakthrough Nitric Oxide discovery to combat COVID-19

▴ KNOW Bio announces breakthrough Nitric Oxide discovery to combat COVID-19
Nitric oxide is a molecule produced naturally by the body to regulate blood flow, control inflammation, and defend against invading microorganisms.

KNOW Bio, LLC has generated the first definitive evidence that nitric oxide (NO) can inhibit viral reproduction of SARS-CoV-2, the human coronavirus that causes COVID-19. Nitric oxide is a molecule produced naturally by the body to regulate blood flow, control inflammation, and defend against invading microorganisms.

These milestone in-vitro experiments were conducted by testing multiple nitric oxide-releasing compounds against wild type SARS-CoV-2 virus at an independent laboratory with a deep history of antiviral research. Therapeutic doses (<200 µM) were applied to infected VERO E6 cells and showed a dose-dependent effect on viral replication. The result was a greater than 99.9% reduction in virus observed after 24 hours versus virus observed on untreated cells. Furthermore, there was no cytotoxic impact (cell damage or cell death) on uninfected cells.

"We are the first to confirm the potent biological activity of nitric oxide against SARS-CoV-2, the novel coronavirus that causes COVID-19," said Neal Hunter, Chief Executive Officer, KNOW Bio, LLC. "As a leader in the development of NO-based therapies, we felt we were best positioned to establish that NO is effective against this virus."

Previous reports have only speculated on the potential of nitric oxide to serve as a therapeutic for patients with COVID-19 or as a preventative countermeasure for those who are at risk of exposure to the virus.1 These conjectures were based in large part on prior published scientific evidence derived from studies conducted on the original SARS-CoV virus.

"The expansive literature supporting nitric oxide's function as a broad-spectrum antimicrobial, shows that nitric oxide-based approaches can play a role in preventing, limiting, and/or treating the pulmonary consequences of COVID-19," said Mark Schoenfisch, Ph.D., Chief Scientific Officer, KNOW Bio, LLC.

Nitric Oxide (NO) has been reported to:

Inhibit coronavirus infection by altering spike protein binding and disrupting the ability of the virus to attach to the receptor and infect human cells.2
Inhibit coronavirus viral replication inside an infected cell by slowing viral RNA production - resulting in fewer RNA strands and viral copies.3
Inhibit release of reproduced virus by preventing host cell death via interfering with caspase activity - the reproduced virus particles thus remain within the infected cell and fewer virus particles are spread to infect other cells.4
"We have gained new understandings into the effective concentrations, rates of release and mechanism of action of nitric oxide against human coronavirus - providing valuable insights into safety and efficacy," continued Schoenfisch.

Submission for publication and peer review is expected before year end.

"There are millions of lives being disrupted and hundreds of thousands lost to this frightening virus," Hunter continued. "Our findings clearly show that nitric oxide-based therapeutics must be a part of any well-thought response to the COVID-19 pandemic."

Tags : #KnowBio #NitriocOxide #NitricOxideinTreatingCovid #CovidTreatmentBreakthrough #LatestCovidTreatmentNewsSep14 #LatestPharmaNewsUpdateSep14

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024